• About us
• Contact

Advertisement

Organisation › Details

Novo Ventures

Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life sciences investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. For more information: https://www.novoholdings.dk/ Novo Ventures is a global team of investment professionals that supports Novo Holdings’ investments in private and public opportunities in the life sciences industry. *

 

	Start	2011-05-03 existent
	Group	Novo Group (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Nielsen, Jack B. (Novo Capital 202101 formerly 201411 Partner at Novo Ventures)
	Person 2	Lüneborg, Nanna (Forbion 202109– General Partner before Novo Ventures + Apposite Capital + Cancer Research UK)
	Region	Hellerup
	Country	Denmark
	Street	19 Tuborg Havnevej
	City	2900 Hellerup
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Hummingbird Bioscience. (5/18/21). "Press Release: Hummingbird Bioscience Raises US$125 Million in Series C Financing". Singapore.
		Record changed: 2024-03-20

Advertisement

More documents for Novo Group (Group)

• [1] Coave Therapeutics (Horama S.A.). (1/9/25). "Press Release: Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines". Paris....
• [2] Single Use Support GmbH. (12/16/24). "Press Release: Darren Verlenden New CEO of Single Use Support". Kufstein....
• [3] Kivu Bioscience. (10/28/24). "Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates". San Francisco, CA....
• [4] Booster Therapeutics GmbH. (10/10/24). "Press Release: Booster Therapeutics Launches to Pioneer New Class of Proteasome Activator Medicines for the Treatment of a Range of Complex Diseases". Berlin....
• [5] Evotec SE. (9/26/24). "Press Release: Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-generation Cell Therapies". Hamburg....
• [6] NanoVation Therapeutics Inc.. (9/18/24). "Press Release: NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases". Vancouver, BC....
• [7] Asceneuron S.A.. (7/16/24). "Press Release: Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases". Lausanne & San Francisco, CA....
• [8] Myricx Pharma Ltd.. (7/8/24). "Press Release: Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development". London....
• [9] Single Use Support GmbH. (5/15/24). "Press Release: Novo Holdings Acquires Majority Stake in Single Use Support". Kufstein....
• [10] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.